Pfizer Dodges More Sanctions In Neurontin Antitrust MDL

Law360, New York (July 7, 2011, 3:44 PM EDT) -- A magistrate judge refused Tuesday to sanction Pfizer Inc. by striking its denial that it promoted off-label uses of epilepsy drug Neurontin, the latest in a New Jersey multidistrict litigation claiming the drugmaker used patent litigation to delay generic competition.

Magistrate Judge Patty Shwartz rejected requests by the class action plaintiffs that the federal court consider their off-label use allegations as established and block Pfizer from presenting evidence or arguments to the contrary. The suit, part of the MDL, was brought by direct purchasers of the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.